Qube Research & Technologies (QRT)
CNTA

Qube Research & Technologies (QRT)’s Centessa Pharmaceuticals CNTA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9M Buy
628,049
+249,309
+66% +$6.38M 0.03% 761
2025
Q4 		$9.47M Buy
+378,740
New +$9.59M 0.01% 1380
2025
Q3 		– Sell
-307,880
Closed -$4.05M – 3616
2025
Q2 		$4.05M Buy
307,880
+278,446
+946% +$3.53M ﹤0.01% 1833
2025
Q1 		$423K Sell
29,434
-77,624
-73% -$1.27M ﹤0.01% 2601
2024
Q4 		$1.79M Buy
107,058
+10,543
+11% +$175K ﹤0.01% 1923
2024
Q3 		$1.54M Buy
96,515
+92,992
+2,640% +$1.14M ﹤0.01% 1867
2024
Q2 		$31.8K Sell
3,523
-5,421
-61% -$51.4K ﹤0.01% 2815
2024
Q1 		$101K Buy
8,944
+7,633
+582% +$72.3K ﹤0.01% 3291
2023
Q4 		$10.4K Buy
1,311
+1,242
+1,800% +$8.33K ﹤0.01% 3602
2023
Q3 		$446 Buy
+69
New +$472 ﹤0.01% 3686

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CNTA Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Centessa Pharmaceuticals (CNTA) stake by 66% in Q1 2026, buying an estimated $6.38M and bringing the position to 628,049 shares worth $24.9M. The position accounts for 0.03% of the portfolio, ranked #761.

Qube Research & Technologies (QRT) first reported a position in CNTA in Q3 2023 and has held it in 10 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Qube Research & Technologies (QRT) held 628,049 shares of Centessa Pharmaceuticals worth $24.9M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 249,309 Centessa Pharmaceuticals shares in Q1 2026, an estimated $6.38M.
  • Centessa Pharmaceuticals made up 0.03% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #761 holding.
  • Qube Research & Technologies (QRT) first reported a position in Centessa Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.